Neuphoria Therapeutics NEUP
NASDAQ NEUP
$2.71 +0.02 (+0.74%)
At close: Nov 11, 2026 · 4:00 PM EST

Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025)

Updated

Neuphoria Therapeutics (NEUP) recorded EBITDA Margin of -1344.62% in FY2026 (year ended Jun 30, 2026), down 1341.65 percentage points from -2.98% in FY2025.

Analysis

Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025) Analysis & Trends

  • Annual EBITDA Margin has a three-year change of +143340.06 percentage points (FY2023 to FY2026).
  • The FY2026 figure is the lowest annual EBITDA Margin since FY2023.
  • Per Business Quant data, NEUP's EBITDA Margin was -2.98% in FY2025 and -144684.68% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Neuphoria Therapeutics 335.34 Mn 260.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 80.95%
Dec 31, 2024 -533.77%
API Access

Neuphoria Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NEUP&period=max&api_key=YOUR_API_KEY